Tertiary lymphoid structures in cancer
Tertiary lymphoid structures in cancer
Tertiary lymphoid structures (TLSs) are lymphoid formations that are found in nonlymphoid tissues. TLS can develop in inflamed tissues and are associated with chronic inflammatory disorders, autoimmunity, and cancer. In the setting of tumors, TLSs facilitate the influx of immune cells into the tumor site and have therefore attracted interest as a means of improving anticancer immunity and favorable treatment response in patients. Schumacher and Thommen review the biology of TLSs and outline recent advances in TLS research. They discuss how TLSs are detected and defined, the mechanism(s) of formation in cancer, and the potential of targeting TLSs for therapeutic benefit. —PNK
Structured Abstract
BACKGROUND
Tertiary lymphoid structures (TLSs) are organized aggregates of immune cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological conditions but arise in the context of chronic inflammation, such as in autoimmune disease, chronic infection, and cancer. With few exceptions, the presence of TLSs in tumors correlates with better prognosis and clinical outcome upon immunotherapy, but, in spite of their presumed importance, the drivers of TLS formation in cancer and the contribution of these structures to intratumoral immune responses remain incompletely understood.
ADVANCES
TLSs resemble secondary lymphoid organs (SLOs) anatomically, and it was originally assumed that their formation would largely be induced by the same stimuli. However, the cell pools and signals that provide inductive stimuli for TLS formation are at least partially different. For instance, several observations suggest that tumor-specific T and B cell immunity may induce some of the molecular factors required for TLS formation and maintenance, and heterogeneity in these drivers may result in distinct TLS states.
It has been speculated that TLSs recapitulate SLO functions at the inflamed tissue site, and available evidence suggests that a contribution of TLSs to the strength of tumor-specific immune responses is plausible. However, whether such a contribution primarily involves the boosting of T cell responses generated in SLOs or the development of new T and B cell reactivities remains a key unanswered question. In addition, the presence of TLSs at the tumor site may offer the possibility for the generation of qualitatively distinct immune responses. Specifically, because TLSs are not encapsulated, exposure of TLS-resident immune cells to macromolecules from the inflamed microenvironment appears to be a realistic possibility, and this could potentially sculpt the nature of intratumoral immune responses. Finally, recent studies suggest a role for TLSs in the clinical response to immune checkpoint blockade, which may make these structures attractive therapeutic targets. However, the development of such strategies should take into account the possible consequences of ectopic formation of lymphoid tissue at other body sites.
OUTLOOK
The prognostic and predictive value of TLSs in cancer has strengthened the interest in these structures as potential mediators of antitumor immunity. Although TLSs have been identified in many cancer types, the markers used to define and characterize TLSs have often varied across studies, complicating efforts to compare predictive value and to assess TLS heterogeneity between cancer types. Thus, the development of standardized approaches to measure TLS number and composition is likely to further reveal their predictive and prognostic value in different disease settings. Related to this, a more comprehensive characterization of TLSs may potentially lead to the identification of a spectrum of TLS states, based on aspects such as cellular composition, location, maturation, and function. Similar to the definition of T cell states in cancer, which has substantially improved our understanding of the role of specific T cell populations in tumor-specific immunity, the molecular definition of TLS states may help to improve their value as prognostic and predictive markers. Finally, a better appreciation of TLS function and the potential contribution of TLSs to autoimmune toxicity will be important to maximize their value as therapeutic targets.
Defining TLS states.
The molecular definition of TLS states may advance their use as prognostic and predictive markers. Characteristics that will provide insight into the diversity of TLS states include their cellular composition, location, and maturation; properties of their cytokine and chemokine environment; and their B cell receptor (BCR) and T cell receptor (TCR) repertoires. AID, activation-induced cytidine deaminase; CTL, cytotoxic T lymphocyte; FRCs, follicular reticular cells; FDCs, follicular dendritic cells; HEVs, high endothelial venules; Ig, immunoglobulin; TFH, T follicular helper cell; TH, T helper cell; Treg, regulatory T cell.
Abstract
Ectopic lymphoid aggregates, termed tertiary lymphoid structures (TLSs), are formed in numerous cancer types, and, with few exceptions, their presence is associated with superior prognosis and response to immunotherapy. In spite of their presumed importance, the triggers that lead to TLS formation in cancer tissue and the contribution of these structures to intratumoral immune responses remain incompletely understood. Here, we discuss the present knowledge on TLSs in cancer, focusing on (i) the drivers of TLS formation, (ii) the function and contribution of TLSs to the antitumor immune response, and (iii) the potential of TLSs as therapeutic targets in human cancers.
Get full access to this article
View all available purchase options and get full access to this article.
Already a Subscriber?Sign In
References and Notes
1
J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P.-H. Cugnenc, Z. Trajanoski, W.-H. Fridman, F. Pagès, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
2
F. Pagès, B. Mlecnik, F. Marliot, G. Bindea, F.-S. Ou, C. Bifulco, A. Lugli, I. Zlobec, T. T. Rau, M. D. Berger, I. D. Nagtegaal, E. Vink-Börger, A. Hartmann, C. Geppert, J. Kolwelter, S. Merkel, R. Grützmann, M. Van den Eynde, A. Jouret-Mourin, A. Kartheuser, D. Léonard, C. Remue, J. Y. Wang, P. Bavi, M. H. A. Roehrl, P. S. Ohashi, L. T. Nguyen, S. Han, H. L. MacGregor, S. Hafezi-Bakhtiari, B. G. Wouters, G. V. Masucci, E. K. Andersson, E. Zavadova, M. Vocka, J. Spacek, L. Petruzelka, B. Konopasek, P. Dundr, H. Skalova, K. Nemejcova, G. Botti, F. Tatangelo, P. Delrio, G. Ciliberto, M. Maio, L. Laghi, F. Grizzi, T. Fredriksen, B. Buttard, M. Angelova, A. Vasaturo, P. Maby, S. E. Church, H. K. Angell, L. Lafontaine, D. Bruni, C. El Sissy, N. Haicheur, A. Kirilovsky, A. Berger, C. Lagorce, J. P. Meyers, C. Paustian, Z. Feng, C. Ballesteros-Merino, J. Dijkstra, C. van de Water, S. van Lent-van Vliet, N. Knijn, A.-M. Mușină, D.-V. Scripcariu, B. Popivanova, M. Xu, T. Fujita, S. Hazama, N. Suzuki, H. Nagano, K. Okuno, T. Torigoe, N. Sato, T. Furuhata, I. Takemasa, K. Itoh, P. S. Patel, H. H. Vora, B. Shah, J. B. Patel, K. N. Rajvik, S. J. Pandya, S. N. Shukla, Y. Wang, G. Zhang, Y. Kawakami, F. M. Marincola, P. A. Ascierto, D. J. Sargent, B. A. Fox, J. Galon, International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet 391, 2128–2139 (2018).
3
W. H. Fridman, F. Pagès, C. Sautès-Fridman, J. Galon, The immune contexture in human tumours: Impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
4
S. A. Rosenberg, N. P. Restifo, Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
5
D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
6
F. S. Hodi, S. J. O’Day, D. F. McDermott, R. W. Weber, J. A. Sosman, J. B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J. C. Hassel, W. Akerley, A. J. M. van den Eertwegh, J. Lutzky, P. Lorigan, J. M. Vaubel, G. P. Linette, D. Hogg, C. H. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, J. I. Clark, J. D. Wolchok, J. S. Weber, J. Tian, M. J. Yellin, G. M. Nichol, A. Hoos, W. J. Urba, Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
7
S. L. Topalian, C. G. Drake, D. M. Pardoll, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212 (2012).
8
R. S. Herbst, J.-C. Soria, M. Kowanetz, G. D. Fine, O. Hamid, M. S. Gordon, J. A. Sosman, D. F. McDermott, J. D. Powderly, S. N. Gettinger, H. E. K. Kohrt, L. Horn, D. P. Lawrence, S. Rost, M. Leabman, Y. Xiao, A. Mokatrin, H. Koeppen, P. S. Hegde, I. Mellman, D. S. Chen, F. S. Hodi, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
9
P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. M. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A. N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A. J. Gutierrez, T. R. Grogan, C. Mateus, G. Tomasic, J. A. Glaspy, R. O. Emerson, H. Robins, R. H. Pierce, D. A. Elashoff, C. Robert, A. Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
10
F. Azimi, R. A. Scolyer, P. Rumcheva, M. Moncrieff, R. Murali, S. W. McCarthy, R. P. Saw, J. F. Thompson, Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 30, 2678–2683 (2012).
11
P. Savas, B. Virassamy, C. Ye, A. Salim, C. P. Mintoff, F. Caramia, R. Salgado, D. J. Byrne, Z. L. Teo, S. Dushyanthen, A. Byrne, L. Wein, S. J. Luen, C. Poliness, S. S. Nightingale, A. S. Skandarajah, D. E. Gyorki, C. M. Thornton, P. A. Beavis, S. B. Fox, P. K. Darcy, T. P. Speed, L. K. Mackay, P. J. Neeson, S. Loi, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
12
L. Keren, M. Bosse, D. Marquez, R. Angoshtari, S. Jain, S. Varma, S.-R. Yang, A. Kurian, D. Van Valen, R. West, S. C. Bendall, M. Angelo, A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell 174, 1373–1387.e19 (2018).
13
M. C. Dieu-Nosjean, N. A. Giraldo, H. Kaplon, C. Germain, W. H. Fridman, C. Sautès-Fridman, Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271, 260–275 (2016).
14
C. Sautès-Fridman, M. Lawand, N. A. Giraldo, H. Kaplon, C. Germain, W. H. Fridman, M.-C. Dieu-Nosjean, Tertiary lymphoid structures in cancers: Prognostic value, regulation, and manipulation for therapeutic intervention. Front. Immunol. 7, 407 (2016).
15
B. A. Helmink, S. M. Reddy, J. Gao, S. Zhang, R. Basar, R. Thakur, K. Yizhak, M. Sade-Feldman, J. Blando, G. Han, V. Gopalakrishnan, Y. Xi, H. Zhao, R. N. Amaria, H. A. Tawbi, A. P. Cogdill, W. Liu, V. S. LeBleu, F. G. Kugeratski, S. Patel, M. A. Davies, P. Hwu, J. E. Lee, J. E. Gershenwald, A. Lucci, R. Arora, S. Woodman, E. Z. Keung, P.-O. Gaudreau, A. Reuben, C. N. Spencer, E. M. Burton, L. E. Haydu, A. J. Lazar, R. Zapassodi, C. W. Hudgens, D. A. Ledesma, S. Ong, M. Bailey, S. Warren, D. Rao, O. Krijgsman, E. A. Rozeman, D. Peeper, C. U. Blank, T. N. Schumacher, L. H. Butterfield, M. A. Zelazowska, K. M. McBride, R. Kalluri, J. Allison, F. Petitprez, W. H. Fridman, C. Sautès-Fridman, N. Hacohen, K. Rezvani, P. Sharma, M. T. Tetzlaff, L. Wang, J. A. Wargo, B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
16
R. Cabrita, M. Lauss, A. Sanna, M. Donia, M. Skaarup Larsen, S. Mitra, I. Johansson, B. Phung, K. Harbst, J. Vallon-Christersson, A. van Schoiack, K. Lövgren, S. Warren, K. Jirström, H. Olsson, K. Pietras, C. Ingvar, K. Isaksson, D. Schadendorf, H. Schmidt, L. Bastholt, A. Carneiro, J. A. Wargo, I. M. Svane, G. Jönsson, Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
17
F. Petitprez, A. de Reyniès, E. Z. Keung, T. W.-W. Chen, C.-M. Sun, J. Calderaro, Y.-M. Jeng, L.-P. Hsiao, L. Lacroix, A. Bougoüin, M. Moreira, G. Lacroix, I. Natario, J. Adam, C. Lucchesi, Y. H. Laizet, M. Toulmonde, M. A. Burgess, V. Bolejack, D. Reinke, K. M. Wani, W.-L. Wang, A. J. Lazar, C. L. Roland, J. A. Wargo, A. Italiano, C. Sautès-Fridman, H. A. Tawbi, W. H. Fridman, B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
18
A. Manzo, M. Bombardieri, F. Humby, C. Pitzalis, Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: From inflammation to autoimmunity and tissue damage/remodeling. Immunol. Rev. 233, 267–285 (2010).
19
O. Thaunat, N. Patey, G. Caligiuri, C. Gautreau, M. Mamani-Matsuda, Y. Mekki, M.-C. Dieu-Nosjean, G. Eberl, R. Ecochard, J.-B. Michel, S. Graff-Dubois, A. Nicoletti, Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J. Immunol. 185, 717–728 (2010).
20
K. Neyt, F. Perros, C. H. GeurtsvanKessel, H. Hammad, B. N. Lambrecht, Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 33, 297–305 (2012).
21
E. J. Colbeck, A. Ager, A. Gallimore, G. W. Jones, Tertiary lymphoid structures in cancer: Drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front. Immunol. 8, 1830 (2017).
22
M. C. Dieu-Nosjean, M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, S. Lebecque, W.-H. Fridman, J. Cadranel, Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26, 4410–4417 (2008).
23
L. de Chaisemartin, J. Goc, D. Damotte, P. Validire, P. Magdeleinat, M. Alifano, I. Cremer, W.-H. Fridman, C. Sautès-Fridman, M.-C. Dieu-Nosjean, Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71, 6391–6399 (2011).
24
J. Goc, C. Germain, T. K. D. Vo-Bourgais, A. Lupo, C. Klein, S. Knockaert, L. de Chaisemartin, H. Ouakrim, E. Becht, M. Alifano, P. Validire, R. Remark, S. A. Hammond, I. Cremer, D. Damotte, W.-H. Fridman, C. Sautès-Fridman, M.-C. Dieu-Nosjean, Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74, 705–715 (2014).
25
F. Bergomas, F. Grizzi, A. Doni, S. Pesce, L. Laghi, P. Allavena, A. Mantovani, F. Marchesi, Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers 4, 1–10 (2011).
26
D. Coppola, M. Nebozhyn, F. Khalil, H. Dai, T. Yeatman, A. Loboda, J. J. Mulé, Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179, 37–45 (2011).
27
C. Sautès-Fridman, F. Petitprez, J. Calderaro, W. H. Fridman, Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307–325 (2019).
28
C. Gu-Trantien, S. Loi, S. Garaud, C. Equeter, M. Libin, A. de Wind, M. Ravoet, H. Le Buanec, C. Sibille, G. Manfouo-Foutsop, I. Veys, B. Haibe-Kains, S. K. Singhal, S. Michiels, F. Rothé, R. Salgado, H. Duvillier, M. Ignatiadis, C. Desmedt, D. Bron, D. Larsimont, M. Piccart, C. Sotiriou, K. Willard-Gallo, CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).
29
D. R. Kroeger, K. Milne, B. H. Nelson, Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer. Clin. Cancer Res. 22, 3005–3015 (2016).
30
A. Hennequin, V. Derangère, R. Boidot, L. Apetoh, J. Vincent, D. Orry, J. Fraisse, S. Causeret, F. Martin, L. Arnould, F. Beltjens, F. Ghiringhelli, S. Ladoire, Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. OncoImmunology 5, e1054598 (2015).
31
G. Di Caro, F. Bergomas, F. Grizzi, A. Doni, P. Bianchi, A. Malesci, L. Laghi, P. Allavena, A. Mantovani, F. Marchesi, Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147–2158 (2014).
32
T. P. McMullen, R. Lai, L. Dabbagh, T. M. Wallace, C. J. de Gara, Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin. Exp. Immunol. 161, 81–88 (2010).
33
M. Baratin, L. Simon, A. Jorquera, C. Ghigo, D. Dembele, J. Nowak, R. Gentek, S. Wienert, F. Klauschen, B. Malissen, M. Dalod, M. Bajénoff, T cell zone resident macrophages silently dispose of apoptotic cells in the lymph node. Immunity 47, 349–362.e5 (2017).
34
F. Barone, D. H. Gardner, S. Nayar, N. Steinthal, C. D. Buckley, S. A. Luther, Stromal fibroblasts in tertiary lymphoid structures: A novel target in chronic inflammation. Front. Immunol. 7, 477 (2016).
35
C. S. Jansen, N. Prokhnevska, V. A. Master, M. G. Sanda, J. W. Carlisle, M. A. Bilen, M. Cardenas, S. Wilkinson, R. Lake, A. G. Sowalsky, R. M. Valanparambil, W. H. Hudson, D. McGuire, K. Melnick, A. I. Khan, K. Kim, Y. M. Chang, A. Kim, C. P. Filson, M. Alemozaffar, A. O. Osunkoya, P. Mullane, C. Ellis, R. Akondy, S. J. Im, A. O. Kamphorst, A. Reyes, Y. Liu, H. Kissick, An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465–470 (2019).
36
I. Siddiqui, K. Schaeuble, V. Chennupati, S. A. Fuertes Marraco, S. Calderon-Copete, D. Pais Ferreira, S. J. Carmona, L. Scarpellino, D. Gfeller, S. Pradervand, S. A. Luther, D. E. Speiser, W. Held, Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019).
37
S. Kurtulus, A. Madi, G. Escobar, M. Klapholz, J. Nyman, E. Christian, M. Pawlak, D. Dionne, J. Xia, O. Rozenblatt-Rosen, V. K. Kuchroo, A. Regev, A. C. Anderson, Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity 50, 181–194.e6 (2019).
38
B. C. Miller, D. R. Sen, R. Al Abosy, K. Bi, Y. V. Virkud, M. W. LaFleur, K. B. Yates, A. Lako, K. Felt, G. S. Naik, M. Manos, E. Gjini, J. R. Kuchroo, J. J. Ishizuka, J. L. Collier, G. K. Griffin, S. Maleri, D. E. Comstock, S. A. Weiss, F. D. Brown, A. Panda, M. D. Zimmer, R. T. Manguso, F. S. Hodi, S. J. Rodig, A. H. Sharpe, W. N. Haining, Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).
39
T. D. Randall, D. M. Carragher, J. Rangel-Moreno, Development of secondary lymphoid organs. Annu. Rev. Immunol. 26, 627–650 (2008).
40
S. A. van de Pavert, R. E. Mebius, New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10, 664–674 (2010).
41
T. Cupedo, G. Kraal, R. E. Mebius, The role of CD45+CD4+CD3− cells in lymphoid organ development. Immunol. Rev. 189, 41–50 (2002).
42
R. E. Mebius, Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3, 292–303 (2003).
43
S. Nishikawa, K. Honda, P. Vieira, H. Yoshida, Organogenesis of peripheral lymphoid organs. Immunol. Rev. 195, 72–80 (2003).
44
T. Cupedo, R. E. Mebius, Role of chemokines in the development of secondary and tertiary lymphoid tissues. Semin. Immunol. 15, 243–248 (2003).
45
D. L. Drayton, S. Liao, R. H. Mounzer, N. H. Ruddle, Lymphoid organ development: From ontogeny to neogenesis. Nat. Immunol. 7, 344–353 (2006).
46
Y. Okabe, R. Medzhitov, Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832–844 (2014).
47
S. A. Luther, K. M. Ansel, J. G. Cyster, Overlapping roles of CXCL13, interleukin 7 receptor α, and CCR7 ligands in lymph node development. J. Exp. Med. 197, 1191–1198 (2003).
48
H. Yoshida, A. Naito, J. Inoue, M. Satoh, S. M. Santee-Cooper, C. F. Ware, A. Togawa, S. Nishikawa, S. Nishikawa, Different cytokines induce surface lymphotoxin-αβ on IL-7 receptor-α cells that differentially engender lymph nodes and Peyer’s patches. Immunity 17, 823–833 (2002).
49
H. Fleige, S. Ravens, G. L. Moschovakis, J. Bölter, S. Willenzon, G. Sutter, S. Häussler, U. Kalinke, I. Prinz, R. Förster, IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J. Exp. Med. 211, 643–651 (2014).
50
S. A. Luther, A. Bidgol, D. C. Hargreaves, A. Schmidt, Y. Xu, J. Paniyadi, M. Matloubian, J. G. Cyster, Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169, 424–433 (2002).
51
S. A. Luther, T. Lopez, W. Bai, D. Hanahan, J. G. Cyster, BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12, 471–481 (2000).
52
N. H. Ruddle, Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 124, 953–959 (2014).
53
C. Gago da Graça, L. G. M. van Baarsen, R. E. Mebius, Tertiary lymphoid structures: Diversity in their development, composition, and role. J. Immunol. 206, 273–281 (2021).
54
C. Deteix, V. Attuil-Audenis, A. Duthey, N. Patey, B. McGregor, V. Dubois, G. Caligiuri, S. Graff-Dubois, E. Morelon, O. Thaunat, Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J. Immunol. 184, 5344–5351 (2010).
55
A. Peters, L. A. Pitcher, J. M. Sullivan, M. Mitsdoerffer, S. E. Acton, B. Franz, K. Wucherpfennig, S. Turley, M. C. Carroll, R. A. Sobel, E. Bettelli, V. K. Kuchroo, Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986–996 (2011).
56
P. Carrega, F. Loiacono, E. Di Carlo, A. Scaramuccia, M. Mora, R. Conte, R. Benelli, G. M. Spaggiari, C. Cantoni, S. Campana, I. Bonaccorsi, B. Morandi, M. Truini, M. C. Mingari, L. Moretta, G. Ferlazzo, NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun. 6, 8280 (2015).
57
J. D. Peske, E. D. Thompson, L. Gemta, R. A. Baylis, Y.-X. Fu, V. H. Engelhard, Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).
58
A. B. Rodriguez, J. D. Peske, A. N. Woods, K. M. Leick, I. S. Mauldin, M. O. Meneveau, S. J. Young, R. S. Lindsay, M. M. Melssen, S. Cyranowski, G. Parriott, M. R. Conaway, Y.-X. Fu, C. L. Slingluff Jr., V. H. Engelhard, Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).
59
M. Lochner, C. Ohnmacht, L. Presley, P. Bruhns, M. Si-Tahar, S. Sawa, G. Eberl, Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORγt and LTi cells. J. Exp. Med. 208, 125–134 (2011).
60
K. Guedj, J. Khallou-Laschet, M. Clement, M. Morvan, A.-T. Gaston, G. Fornasa, J. Dai, M. Gervais-Taurel, G. Eberl, J.-B. Michel, G. Caligiuri, A. Nicoletti, M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc. Res. 101, 434–443 (2014).
61
T. D. Randall, Bronchus-associated lymphoid tissue (BALT) structure and function. Adv. Immunol. 107, 187–241 (2010).
62
J. Rangel-Moreno, D. M. Carragher, M. de la Luz Garcia-Hernandez, J. Y. Hwang, K. Kusser, L. Hartson, J. K. Kolls, S. A. Khader, T. D. Randall, The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639–646 (2011).
63
K. Guedj, Y. Abitbol, D. Cazals-Hatem, M. Morvan, L. Maggiori, Y. Panis, Y. Bouhnik, G. Caligiuri, O. Corcos, A. Nicoletti, Adipocytes orchestrate the formation of tertiary lymphoid organs in the creeping fat of Crohn’s disease affected mesentery. J. Autoimmun. 103, 102281 (2019).
64
K. Guedj, J. Khallou-Laschet, M. Clement, M. Morvan, S. Delbosc, A.-T. Gaston, F. Andreata, Y. Castier, C. Deschildre, J.-B. Michel, G. Caligiuri, A. Nicoletti, Inflammatory micro-environmental cues of human atherothrombotic arteries confer to vascular smooth muscle cells the capacity to trigger lymphoid neogenesis. PLOS ONE 9, e116295 (2014).
65
D. S. Thommen, V. H. Koelzer, P. Herzig, A. Roller, M. Trefny, S. Dimeloe, A. Kiialainen, J. Hanhart, C. Schill, C. Hess, S. Savic Prince, M. Wiese, D. Lardinois, P.-C. Ho, C. Klein, V. Karanikas, K. D. Mertz, T. N. Schumacher, A. Zippelius, A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat. Med. 24, 994–1004 (2018).
66
M. Yang, J. Lu, G. Zhang, Y. Wang, M. He, Q. Xu, C. Xu, H. Liu, CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. J. Immunother. Cancer 9, e001136 (2021).
67
S. Z. Wu, D. L. Roden, C. Wang, H. Holliday, K. Harvey, A. S. Cazet, K. J. Murphy, B. Pereira, G. Al-Eryani, N. Bartonicek, R. Hou, J. R. Torpy, S. Junankar, C.-L. Chan, C. E. Lam, M. N. Hui, L. Gluch, J. Beith, A. Parker, E. Robbins, D. Segara, C. Mak, C. Cooper, S. Warrier, A. Forrest, J. Powell, S. O’Toole, T. R. Cox, P. Timpson, E. Lim, X. S. Liu, A. Swarbrick, Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 39, e104063 (2020).
68
A. Ager, High endothelial venules and other blood vessels: Critical regulators of lymphoid organ development and function. Front. Immunol. 8, 45 (2017).
69
G. C. Furtado, M. E. Pacer, G. Bongers, C. Bénézech, Z. He, L. Chen, M. C. Berin, G. Kollias, J. H. Caamaño, S. A. Lira, TNFα-dependent development of lymphoid tissue in the absence of RORγt+ lymphoid tissue inducer cells. Mucosal Immunol. 7, 602–614 (2014).
70
M. C. Dieu-Nosjean, J. Goc, N. A. Giraldo, C. Sautès-Fridman, W. H. Fridman, Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35, 571–580 (2014).
71
C. Gu-Trantien, E. Migliori, L. Buisseret, A. de Wind, S. Brohée, S. Garaud, G. Noël, V. L. Dang Chi, J. N. Lodewyckx, C. Naveaux, H. Duvillier, S. Goriely, D. Larsimont, K. Willard-Gallo, CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight 2, e91487 (2017).
72
K. Siliņa, A. Soltermann, F. M. Attar, R. Casanova, Z. M. Uckeley, H. Thut, M. Wandres, S. Isajevs, P. Cheng, A. Curioni-Fontecedro, P. Foukas, M. P. Levesque, H. Moch, A. Linē, M. van den Broek, Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308–1320 (2018).
73
J. Calderaro, F. Petitprez, E. Becht, A. Laurent, T. Z. Hirsch, B. Rousseau, A. Luciani, G. Amaddeo, J. Derman, C. Charpy, J. Zucman-Rossi, W. H. Fridman, C. Sautès-Fridman, Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. J. Hepatol. 70, 58–65 (2019).
74
F. Posch, K. Silina, S. Leibl, A. Mündlein, H. Moch, A. Siebenhüner, P. Samaras, J. Riedl, M. Stotz, J. Szkandera, H. Stöger, M. Pichler, R. Stupp, M. van den Broek, P. Schraml, A. Gerger, U. Petrausch, T. Winder, Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology 7, e1378844 (2017).
75
J. Alsughayyir, G. J. Pettigrew, R. Motallebzadeh, Spoiling for a fight: B lymphocytes as initiator and effector populations within tertiary lymphoid organs in autoimmunity and transplantation. Front. Immunol. 8, 1639 (2017).
76
A. Cipponi, M. Mercier, T. Seremet, J.-F. Baurain, I. Théate, J. van den Oord, M. Stas, T. Boon, P. G. Coulie, N. van Baren, Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72, 3997–4007 (2012).
77
J. S. Nielsen, B. H. Nelson, Tumor-infiltrating B cells and T cells: Working together to promote patient survival. OncoImmunology 1, 1623–1625 (2012).
78
A. Montfort, O. Pearce, E. Maniati, B. G. Vincent, L. Bixby, S. Böhm, T. Dowe, E. H. Wilkes, P. Chakravarty, R. Thompson, J. Topping, P. R. Cutillas, M. Lockley, J. S. Serody, M. Capasso, F. R. Balkwill, A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin. Cancer Res. 23, 250–262 (2017).
79
S. Nzula, J. J. Going, D. I. Stott, Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas. Cancer Res. 63, 3275–3280 (2003).
80
J. A. Coronella, C. Spier, M. Welch, K. T. Trevor, A. T. Stopeck, H. Villar, E. M. Hersh, Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J. Immunol. 169, 1829–1836 (2002).
81
H. A. Schlößer, M. Thelen, A. Lechner, K. Wennhold, M. A. Garcia-Marquez, S. I. Rothschild, E. Staib, T. Zander, D. Beutner, B. Gathof, R. Gilles, E. Cukuroglu, J. Göke, A. Shimabukuro-Vornhagen, U. Drebber, A. Quaas, C. J. Bruns, A. H. Hölscher, M. S. Von Bergwelt-Baildon, B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies. OncoImmunology 8, e1512458 (2018).
82
W. Zhu, C. Germain, Z. Liu, Y. Sebastian, P. Devi, S. Knockaert, P. Brohawn, K. Lehmann, D. Damotte, P. Validire, Y. Yao, V. Valge-Archer, S. A. Hammond, M.-C. Dieu-Nosjean, B. W. Higgs, A high density of tertiary lymphoid structure B cells in lung tumors is associated with increased CD4+ T cell receptor repertoire clonality. OncoImmunology 4, e1051922 (2015).
83
H. H. Workel, J. M. Lubbers, R. Arnold, T. M. Prins, P. van der Vlies, K. de Lange, T. Bosse, I. C. van Gool, F. A. Eggink, M. C. A. Wouters, F. L. Komdeur, E. C. van der Slikke, C. L. Creutzberg, A. Kol, A. Plat, M. Glaire, D. N. Church, H. W. Nijman, M. de Bruyn, A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer. Cancer Immunol. Res. 7, 784–796 (2019).
84
E. J. Colbeck, E. Jones, J. P. Hindley, K. Smart, R. Schulz, M. Browne, S. Cutting, A. Williams, L. Parry, A. Godkin, C. F. Ware, A. Ager, A. Gallimore, Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunol. Res. 5, 1005–1015 (2017).
85
S. Stranford, N. H. Ruddle, Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: Parallels with lymph node stroma. Front. Immunol. 3, 350 (2012).
86
C. H. GeurtsvanKessel, M. A. M. Willart, I. M. Bergen, L. S. van Rijt, F. Muskens, D. Elewaut, A. D. M. E. Osterhaus, R. Hendriks, G. F. Rimmelzwaan, B. N. Lambrecht, Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339–2349 (2009).
87
S. Halle, H. C. Dujardin, N. Bakocevic, H. Fleige, H. Danzer, S. Willenzon, Y. Suezer, G. Hämmerling, N. Garbi, G. Sutter, T. Worbs, R. Förster, Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 206, 2593–2601 (2009).
88
R. M. Genta, H. W. Hamner, D. Y. Graham, Gastric lymphoid follicles in Helicobacter pylori infection: Frequency, distribution, and response to triple therapy. Hum. Pathol. 24, 577–583 (1993).
89
J. Goc, W. H. Fridman, C. Sautès-Fridman, M. C. Dieu-Nosjean, Characteristics of tertiary lymphoid structures in primary cancers. OncoImmunology 2, e26836 (2013).
90
P. Jézéquel, O. Kerdraon, H. Hondermarck, C. Guérin-Charbonnel, H. Lasla, W. Gouraud, J.-L. Canon, A. Gombos, F. Dalenc, S. Delaloge, J. Lemonnier, D. Loussouarn, V. Verrièle, M. Campone, Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. Breast Cancer Res. 21, 65 (2019).
91
C. Pfannstiel, P. L. Strissel, K. B. Chiappinelli, D. Sikic, S. Wach, R. M. Wirtz, A. Wullweber, H. Taubert, J. Breyer, W. Otto, T. Worst, M. Burger, B. Wullich, C. Bolenz, N. Fuhrich, C. I. Geppert, V. Weyerer, R. Stoehr, S. Bertz, B. Keck, F. Erlmeier, P. Erben, A. Hartmann, R. Strick, M. Eckstein, BRIDGE Consortium, Germany; BRIDGE Consortium, Germany, BRIDGE Consortium, Germany, BRIDGE Consortium, Germany, The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol. Res. 7, 923–938 (2019).
92
J. P. Hindley, E. Jones, K. Smart, H. Bridgeman, S. N. Lauder, B. Ondondo, S. Cutting, K. Ladell, K. K. Wynn, D. Withers, D. A. Price, A. Ager, A. J. Godkin, A. M. Gallimore, T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 72, 5473–5482 (2012).
93
P. De Silva, S. Garaud, C. Solinas, A. de Wind, G. Van den Eyden, V. Jose, C. Gu-Trantien, E. Migliori, A. Boisson, C. Naveaux, H. Duvillier, L. Craciun, D. Larsimont, M. Piccart-Gebhart, K. Willard-Gallo, FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine 39, 226–238 (2019).
94
T. Junt, E. Scandella, B. Ludewig, Form follows function: Lymphoid tissue microarchitecture in antimicrobial immune defence. Nat. Rev. Immunol. 8, 764–775 (2008).
95
T. C. Bruno, New predictors for immunotherapy responses sharpen our view of the tumour microenvironment. Nature 577, 474–476 (2020).
96
S. Salomonsson, M. V. Jonsson, K. Skarstein, K. A. Brokstad, P. Hjelmström, M. Wahren-Herlenius, R. Jonsson, Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome. Arthritis Rheum. 48, 3187–3201 (2003).
97
G. P. Sims, H. Shiono, N. Willcox, D. I. Stott, Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J. Immunol. 167, 1935–1944 (2001).
98
M. P. Armengol, M. Juan, A. Lucas-Martín, M. T. Fernández-Figueras, D. Jaraquemada, T. Gallart, R. Pujol-Borrell, Thyroid autoimmune disease: Demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am. J. Pathol. 159, 861–873 (2001).
99
C. Germain, S. Gnjatic, F. Tamzalit, S. Knockaert, R. Remark, J. Goc, A. Lepelley, E. Becht, S. Katsahian, G. Bizouard, P. Validire, D. Damotte, M. Alifano, P. Magdeleinat, I. Cremer, J.-L. Teillaud, W.-H. Fridman, C. Sautès-Fridman, M.-C. Dieu-Nosjean, Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189, 832–844 (2014).
100
Y. Lee, R. K. Chin, P. Christiansen, Y. Sun, A. V. Tumanov, J. Wang, A. V. Chervonsky, Y.-X. Fu, Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 25, 499–509 (2006).
101
E. J. McMahon, S. L. Bailey, C. V. Castenada, H. Waldner, S. D. Miller, Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11, 335–339 (2005).
102
J. E. Moyron-Quiroz, J. Rangel-Moreno, K. Kusser, L. Hartson, F. Sprague, S. Goodrich, D. L. Woodland, F. E. Lund, T. D. Randall, Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927–934 (2004).
103
J. Rangel-Moreno, J. E. Moyron-Quiroz, L. Hartson, K. Kusser, T. D. Randall, Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. U.S.A. 104, 10577–10582 (2007).
104
J. E. Moyron-Quiroz, J. Rangel-Moreno, L. Hartson, K. Kusser, M. P. Tighe, K. D. Klonowski, L. Lefrançois, L. S. Cauley, A. G. Harmsen, F. E. Lund, T. D. Randall, Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643–654 (2006).
105
D. Schrama, P. thor Straten, W. H. Fischer, A. D. McLellan, E.-B. Bröcker, R. A. Reisfeld, J. C. Becker, Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14, 111–121 (2001).
106
D. Schrama, H. Voigt, A. O. Eggert, R. Xiang, H. Zhou, T. N. M. Schumacher, M. H. Andersen, P. thor Straten, R. A. Reisfeld, J. C. Becker, Immunological tumor destruction in a murine melanoma model by targeted LTα independent of secondary lymphoid tissue. Cancer Immunol. Immunother. 57, 85–95 (2008).
107
G. Oliveira, K. Stromhaug, S. Klaeger, T. Kula, D. T. Frederick, P. M. Le, J. Forman, T. Huang, S. Li, W. Zhang, Q. Xu, N. Cieri, K. R. Clauser, S. A. Shukla, D. Neuberg, S. Justesen, G. MacBeath, S. A. Carr, E. F. Fritsch, N. Hacohen, M. Sade-Feldman, K. J. Livak, G. M. Boland, P. A. Ott, D. B. Keskin, C. J. Wu, Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature 596, 119–125 (2021).
108
J. X. Caushi, J. Zhang, Z. Ji, A. Vaghasia, B. Zhang, E. H.-C. Hsiue, B. J. Mog, W. Hou, S. Justesen, R. Blosser, A. Tam, V. Anagnostou, T. R. Cottrell, H. Guo, H. Y. Chan, D. Singh, S. Thapa, A. G. Dykema, P. Burman, B. Choudhury, L. Aparicio, L. S. Cheung, M. Lanis, Z. Belcaid, M. El Asmar, P. B. Illei, R. Wang, J. Meyers, K. Schuebel, A. Gupta, A. Skaist, S. Wheelan, J. Naidoo, K. A. Marrone, M. Brock, J. Ha, E. L. Bush, B. J. Park, M. Bott, D. R. Jones, J. E. Reuss, V. E. Velculescu, J. E. Chaft, K. W. Kinzler, S. Zhou, B. Vogelstein, J. M. Taube, M. D. Hellmann, J. R. Brahmer, T. Merghoub, P. M. Forde, S. Yegnasubramanian, H. Ji, D. M. Pardoll, K. N. Smith, Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126–132 (2021).
109
C. D. Buckley, F. Barone, S. Nayar, C. Bénézech, J. Caamaño, Stromal cells in chronic inflammation and tertiary lymphoid organ formation. Annu. Rev. Immunol. 33, 715–745 (2015).
110
J. Goc, W. H. Fridman, S. A. Hammond, C. Sautès-Fridman, M. C. Dieu-Nosjean, Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. OncoImmunology 3, e28976 (2014).
111
N. Hiraoka, Y. Ino, R. Yamazaki-Itoh, Y. Kanai, T. Kosuge, K. Shimada, Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112, 1782–1790 (2015).
112
K. Siliņa, U. Rulle, Z. Kalniņa, A. Linē, Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: A novel anti-cancer treatment avenue? Cancer Immunol. Immunother. 63, 643–662 (2014).
113
W. H. Fridman, L. Zitvogel, C. Sautès-Fridman, G. Kroemer, The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
114
A. R. Cillo, C. H. L. Kürten, T. Tabib, Z. Qi, S. Onkar, T. Wang, A. Liu, U. Duvvuri, S. Kim, R. J. Soose, S. Oesterreich, W. Chen, R. Lafyatis, T. C. Bruno, R. L. Ferris, D. A. A. Vignali, Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity 52, 183–199.e9 (2020).
115
J. L. Messina, D. A. Fenstermacher, S. Eschrich, X. Qu, A. E. Berglund, M. C. Lloyd, M. J. Schell, V. K. Sondak, J. S. Weber, J. J. Mulé, 12-Chemokine gene signature identifies lymph node-like structures in melanoma: Potential for patient selection for immunotherapy? Sci. Rep. 2, 765 (2012).
116
S. Prabhakaran, V. T. Rizk, Z. Ma, C.-H. Cheng, A. E. Berglund, D. Coppola, F. Khalil, J. J. Mulé, H. H. Soliman, Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: Correlation with clinical outcomes. Breast Cancer Res. 19, 71 (2017).
117
A. Kim, S. J. Lee, J. Ahn, W. Y. Park, D. H. Shin, C. H. Lee, H. Kwon, Y. J. Jeong, H. Y. Ahn, H. i, Y. D. Kim, J. S. Cho, The prognostic significance of tumor-infiltrating lymphocytes assessment with hematoxylin and eosin sections in resected primary lung adenocarcinoma. PLOS ONE 14, e0224430 (2019).
118
C. Solinas, D. Marcoux, S. Garaud, J. R. Vitória, G. Van den Eynden, A. de Wind, P. De Silva, A. Boisson, L. Craciun, D. Larsimont, M. Piccart-Gebhart, V. Detours, D. t’Kint de Roodenbeke, K. Willard-Gallo, BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Lett. 450, 88–97 (2019).
119
N. A. Giraldo, E. Becht, F. Pagès, G. Skliris, V. Verkarre, Y. Vano, A. Mejean, N. Saint-Aubert, L. Lacroix, I. Natario, A. Lupo, M. Alifano, D. Damotte, A. Cazes, F. Triebel, G. J. Freeman, M.-C. Dieu-Nosjean, S. Oudard, W. H. Fridman, C. Sautès-Fridman, Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21, 3031–3040 (2015).
120
S. N. Willis, S. S. Mallozzi, S. J. Rodig, K. M. Cronk, S. L. McArdel, T. Caron, G. S. Pinkus, L. Lovato, K. L. Shampain, D. E. Anderson, R. C. E. Anderson, J. N. Bruce, K. C. O’Connor, The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J. Immunol. 182, 3310–3317 (2009).
121
R. Remark, M. Alifano, I. Cremer, A. Lupo, M.-C. Dieu-Nosjean, M. Riquet, L. Crozet, H. Ouakrim, J. Goc, A. Cazes, J.-F. Fléjou, L. Gibault, V. Verkarre, J.-F. Régnard, O.-N. Pagès, S. Oudard, B. Mlecnik, C. Sautès-Fridman, W.-H. Fridman, D. Damotte, Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin. Clin. Cancer Res. 19, 4079–4091 (2013).
122
L. Munoz-Erazo, J. L. Rhodes, V. C. Marion, R. A. Kemp, Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell. Mol. Immunol. 17, 570–575 (2020).
123
S. L. Figenschau, S. Fismen, K. A. Fenton, C. Fenton, E. S. Mortensen, Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15, 101 (2015).
124
N. S. Joshi, E. H. Akama-Garren, Y. Lu, D.-Y. Lee, G. P. Chang, A. Li, M. DuPage, T. Tammela, N. R. Kerper, A. F. Farago, R. Robbins, D. M. Crowley, R. T. Bronson, T. Jacks, Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43, 579–590 (2015).
125
S. Finkin, D. Yuan, I. Stein, K. Taniguchi, A. Weber, K. Unger, J. L. Browning, N. Goossens, S. Nakagawa, G. Gunasekaran, M. E. Schwartz, M. Kobayashi, H. Kumada, M. Berger, O. Pappo, K. Rajewsky, Y. Hoshida, M. Karin, M. Heikenwalder, Y. Ben-Neriah, E. Pikarsky, Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16, 1235–1244 (2015).
126
G. V. Sharonov, E. O. Serebrovskaya, D. V. Yuzhakova, O. V. Britanova, D. M. Chudakov, B cells, plasma cells and antibody repertoires in the tumour microenvironment. Nat. Rev. Immunol. 20, 294–307 (2020).
127
S. Shalapour, J. Font-Burgada, G. Di Caro, Z. Zhong, E. Sanchez-Lopez, D. Dhar, G. Willimsky, M. Ammirante, A. Strasner, D. E. Hansel, C. Jamieson, C. J. Kane, T. Klatte, P. Birner, L. Kenner, M. Karin, Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521, 94–98 (2015).
128
X. Liu, J. Y. S. Tsang, T. Hlaing, J. Hu, Y.-B. Ni, S. K. Chan, S. Y. Cheung, G. M. Tse, Distinct tertiary lymphoid structure associations and their prognostic relevance in HER2 positive and negative breast cancers. Oncologist 22, 1316–1324 (2017).
129
J. Gao, N. Navai, O. Alhalabi, A. Siefker-Radtke, M. T. Campbell, R. S. Tidwell, C. C. Guo, A. M. Kamat, S. F. Matin, J. C. Araujo, A. Y. Shah, P. Msaouel, P. Corn, J. Wang, J. N. Papadopoulos, S. S. Yadav, J. M. Blando, F. Duan, S. Basu, W. Liu, Y. Shen, Y. Zhang, M. D. Macaluso, Y. Wang, J. Chen, J. Zhang, A. Futreal, C. Dinney, J. P. Allison, S. Goswami, P. Sharma, Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat. Med. 26, 1845–1851 (2020).
130
J. Griss, W. Bauer, C. Wagner, M. Simon, M. Chen, K. Grabmeier-Pfistershammer, M. Maurer-Granofszky, F. Roka, T. Penz, C. Bock, G. Zhang, M. Herlyn, K. Glatz, H. Läubli, K. D. Mertz, P. Petzelbauer, T. Wiesner, M. Hartl, W. F. Pickl, R. Somasundaram, P. Steinberger, S. N. Wagner, B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019).
131
L. Buisseret, S. Garaud, A. de Wind, G. Van den Eynden, A. Boisson, C. Solinas, C. Gu-Trantien, C. Naveaux, J.-N. Lodewyckx, H. Duvillier, L. Craciun, I. Veys, D. Larsimont, M. Piccart-Gebhart, J. Stagg, C. Sotiriou, K. Willard-Gallo, Tumor-infiltrating lymphocyte composition, organization and PD-1/PD-L1 expression are linked in breast cancer. OncoImmunology 6, e1257452 (2016).
132
A. Cimino-Mathews, E. Thompson, J. M. Taube, X. Ye, Y. Lu, A. Meeker, H. Xu, R. Sharma, K. Lecksell, T. C. Cornish, N. Cuka, P. Argani, L. A. Emens, PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum. Pathol. 47, 52–63 (2016).
133
A. Johansson-Percival, B. He, Z.-J. Li, A. Kjellén, K. Russell, J. Li, I. Larma, R. Ganss, De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207–1217 (2017).
134
T. R. Cottrell, E. D. Thompson, P. M. Forde, J. E. Stein, A. S. Duffield, V. Anagnostou, N. Rekhtman, R. A. Anders, J. D. Cuda, P. B. Illei, E. Gabrielson, F. B. Askin, N. Niknafs, K. N. Smith, M. J. Velez, J. L. Sauter, J. M. Isbell, D. R. Jones, R. J. Battafarano, S. C. Yang, L. Danilova, J. D. Wolchok, S. L. Topalian, V. E. Velculescu, D. M. Pardoll, J. R. Brahmer, M. D. Hellmann, J. E. Chaft, A. Cimino-Mathews, J. M. Taube, Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: A proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853–1860 (2018).
135
N. van Dijk, A. Gil-Jimenez, K. Silina, K. Hendricksen, L. A. Smit, J. M. de Feijter, M. L. van Montfoort, C. van Rooijen, D. Peters, A. Broeks, H. G. van der Poel, A. Bruining, Y. Lubeck, K. Sikorska, T. N. Boellaard, P. Kvistborg, D. J. Vis, E. Hooijberg, T. N. Schumacher, M. van den Broek, L. F. A. Wessels, C. U. Blank, B. W. van Rhijn, M. S. van der Heijden, Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial. Nat. Med. 26, 1839–1844 (2020).
136
D. P. Hollern, N. Xu, A. Thennavan, C. Glodowski, S. Garcia-Recio, K. R. Mott, X. He, J. P. Garay, K. Carey-Ewend, D. Marron, J. Ford, S. Liu, S. C. Vick, M. Martin, J. S. Parker, B. G. Vincent, J. S. Serody, C. M. Perou, B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell 179, 1191–1206.e21 (2019).
137
S. Sánchez-Alonso, G. Setti-Jerez, M. Arroyo, T. Hernández, M. I. Martos, J. M. Sánchez-Torres, R. Colomer, A. R. Ramiro, A. Alfranca, A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. J. Immunother. Cancer 8, e001187 (2020).
138
P. Voabil, M. de Bruijn, L. M. Roelofsen, S. H. Hendriks, S. Brokamp, M. van den Braber, A. Broeks, J. Sanders, P. Herzig, A. Zippelius, C. U. Blank, K. J. Hartemink, K. Monkhorst, J. B. A. G. Haanen, T. N. Schumacher, D. S. Thommen, An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat. Med. 27, 1250–1261 (2021).
139
R. H. Mounzer, O. S. Svendsen, P. Baluk, C. M. Bergman, T. P. Padera, H. Wiig, R. K. Jain, D. M. McDonald, N. H. Ruddle, Lymphotoxin-alpha contributes to lymphangiogenesis. Blood 116, 2173–2182 (2010).
140
Q. Zhang, Y. Lu, S. T. Proulx, R. Guo, Z. Yao, E. M. Schwarz, B. F. Boyce, L. Xing, Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res. Ther. 9, R118 (2007).
141
S. Rehal, P. Y. von der Weid, TNFΔARE mice display abnormal lymphatics and develop tertiary lymphoid organs in the mesentery. Am. J. Pathol. 187, 798–807 (2017).
142
E. Allen, A. Jabouille, L. B. Rivera, I. Lodewijckx, R. Missiaen, V. Steri, K. Feyen, J. Tawney, D. Hanahan, I. P. Michael, G. Bergers, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, eaak9679 (2017).
143
L. Maldonado, J. E. Teague, M. P. Morrow, I. Jotova, T. C. Wu, C. Wang, C. Desmarais, J. D. Boyer, B. Tycko, H. S. Robins, R. A. Clark, C. L. Trimble, Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci. Transl. Med. 6, 221ra13 (2014).
144
E. R. Lutz, A. A. Wu, E. Bigelow, R. Sharma, G. Mo, K. Soares, S. Solt, A. Dorman, A. Wamwea, A. Yager, D. Laheru, C. L. Wolfgang, J. Wang, R. H. Hruban, R. A. Anders, E. M. Jaffee, L. Zheng, Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol. Res. 2, 616–631 (2014).
145
R. Remark, A. Lupo, M. Alifano, J. Biton, H. Ouakrim, A. Stefani, I. Cremer, J. Goc, J.-F. Régnard, M.-C. Dieu-Nosjean, D. Damotte, Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. OncoImmunology 5, e1255394 (2016).
146
G. Morcrette, T. Z. Hirsch, E. Badour, J. Pilet, S. Caruso, J. Calderaro, Y. Martin, S. Imbeaud, E. Letouzé, S. Rebouissou, S. Branchereau, S. Taque, C. Chardot, C. Guettier, J.-Y. Scoazec, M. Fabre, L. Brugières, J. Zucman-Rossi, APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. OncoImmunology 8, e1583547 (2019).
147
L. H. Calabrese, C. Calabrese, L. C. Cappelli, Rheumatic immune-related adverse events from cancer immunotherapy. Nat. Rev. Rheumatol. 14, 569–579 (2018).
148
S. Matsubara, M. Seki, S. Suzuki, T. Komori, M. Takamori, Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors. J. Immunother. Cancer 7, 256 (2019).
Information & Authors
Information
Published In
Science
Volume 375 | Issue 6576
7 January 2022
7 January 2022
Copyright
Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
This is an article distributed under the terms of the Science Journals Default License.
Submission history
Published in print: 7 January 2022
Acknowledgments
Funding: This work was supported by European Research Council (ERC) Advanced Grant SENSIT (grant agreement no. 742259), the Stevin Award, and the Jeantet-Collen Prize for Translational Medicine (to T.N.S.) and by the Dutch Cancer Society (KWF Young Investigator Grant 12046) (to D.S.T.).
Competing interests: The authors declare that they have no competing interests.
Authors
Funding Information
European Research Council: 742259
Louis-Jeantet Foundation: Jeantet-Collen Prize
KWF Kankerbestrijding: 12046
Stevin Award:
Metrics & Citations
Metrics
Article Usage
Altmetrics
Citations
Export citation
Select the format you want to export the citation of this publication.
View Options
Get Access
Log in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
- Become a AAAS Member
- Activate your Account
- Purchase Access to Other Journals in the Science Family
- Account Help
Log in via OpenAthens.
Log in via Shibboleth.
More options
Purchase digital access to this article
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
View options
PDF format
Download this article as a PDF file
Download PDF